Invivyd (NASDAQ:IVVD) Insider Timothy Edward Lee Sells 20,964 Shares of Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Timothy Edward Lee sold 20,964 shares of Invivyd stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $1.58, for a total transaction of $33,123.12. Following the sale, the insider directly owned 117,717 shares of the company’s stock, valued at $185,992.86. This represents a 15.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Timothy Edward Lee also recently made the following trade(s):

• On Tuesday, February 17th, Timothy Edward Lee sold 19,663 shares of Invivyd stock. The shares were sold at an average price of $1.54, for a total value of $30,281.02.

Invivyd Stock Up 6.5%

NASDAQ:IVVD opened at $1.65 on Thursday. Invivyd, Inc. has a 12-month low of $0.46 and a 12-month high of $3.07. The stock’s fifty day simple moving average is $2.19 and its 200-day simple moving average is $1.75. The firm has a market capitalization of $384.65 million, a P/E ratio of -3.51 and a beta of 0.60.

Key Invivyd News

Here are the key news stories impacting Invivyd this week:

• Negative Sentiment: Jill Andersen sold 34,939 shares on Feb. 18 at an average price of $1.58 (≈$55.2k); her holdings fell ~16.1% to 181,736 shares. SEC Filing
• Negative Sentiment: Jill Andersen sold 32,771 shares on Feb. 17 at $1.54 (≈$50.5k); that trade reduced her position by ~13.1%. SEC Filing
• Negative Sentiment: Timothy Edward Lee sold 20,964 shares on Feb. 18 at $1.58 (≈$33.1k); his stake declined ~15.1% to 117,717 shares. SEC Filing
• Negative Sentiment: Timothy Edward Lee sold 19,663 shares on Feb. 17 at $1.54 (≈$30.3k); his ownership fell ~12.4%. SEC Filing
• Negative Sentiment: William E. Duke (CFO) sold 20,964 shares on Feb. 18 at $1.58 (≈$33.1k); his stake dropped ~16.3% to 107,717 shares. SEC Filing
• Negative Sentiment: William E. Duke sold 19,663 shares on Feb. 17 at $1.54 (≈$30.3k); his position fell ~13.3%. SEC Filing
• Negative Sentiment: Julie Green sold 20,964 shares on Feb. 18 at $1.58 (≈$33.1k); her holdings declined ~16.3% to 107,717 shares. SEC Filing
• Negative Sentiment: Julie Green sold 19,663 shares on Feb. 17 at $1.54 (≈$30.3k); that trade lowered her stake ~13.3%. SEC Filing
• Negative Sentiment: Robert D. Allen III sold 19,392 shares on Feb. 18 at $1.58 (≈$30.6k); his holdings fell ~14.5% to 114,487 shares. SEC Filing
• Negative Sentiment: Robert D. Allen III sold 18,189 shares on Feb. 17 at $1.54 (≈$28.0k); his position declined ~12.0%. SEC Filing

Institutional Investors Weigh In On Invivyd

Several hedge funds have recently bought and sold shares of the company. Courier Capital LLC acquired a new position in Invivyd during the fourth quarter worth approximately $25,000. Bronte Capital Management Pty Ltd. bought a new stake in shares of Invivyd during the fourth quarter worth approximately $27,000. DRW Securities LLC bought a new stake in Invivyd in the 4th quarter valued at $27,000. ProShare Advisors LLC bought a new stake in shares of Invivyd in the fourth quarter valued at about $30,000. Finally, State of Wyoming acquired a new position in shares of Invivyd during the 4th quarter worth approximately $30,000. 70.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on IVVD shares. BTIG Research reaffirmed a “buy” rating on shares of Invivyd in a research note on Wednesday, January 21st. D. Boral Capital restated a “hold” rating on shares of Invivyd in a research report on Tuesday, November 25th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Invivyd in a report on Monday, December 29th. HC Wainwright increased their price target on Invivyd from $5.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Finally, Zacks Research upgraded shares of Invivyd from a “strong sell” rating to a “hold” rating in a report on Thursday, November 13th. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Invivyd presently has an average rating of “Hold” and an average price target of $8.00.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.